Αποτελέσματα Αναζήτησης
22 Φεβ 2023 · Rubius, a biotech that went public in 2018 at a $2 billion valuation, is liquidating its assets after failing to advance its pipeline. The company's flameout is a cautionary tale for investors who backed ultra-risky startups with zero clinical data.
Rubius Therapeutics is developing allogeneic cell therapies based on biologically engineered red blood cells (RBCs) that can stimulate or suppress immune responses. Learn about its RED PLATFORM, RCT candidates, and clinical trials for advanced cancers.
22 Φεβ 2023 · The biotech, which developed cellular therapies based on engineered red blood cells, will liquidate and end operations. Rubius faced multiple challenges in 2022, including dumping its lead candidates and cutting staff, before seeking a sale or merger.
13 Σεπ 2022 · Rubius Therapeutics has torn up its strategy. After reviewing human data on its lead candidates, the cell therapy biotech concluded investment in its two clinical prospects “is no longer...
22 Φεβ 2023 · Rubius Therapeutics on Wednesday revealed plans to shut down and liquidate its assets, four years after it went public at a nearly $2 billion valuation with the goal to re-engineer blood cells to fight disease.
16 Δεκ 2021 · Rubius Therapeutics is a biopharmaceutical company that engineers red blood cells to create cellular medicines for cancer and autoimmune diseases. Learn about its RED PLATFORM, pipeline progress, clinical results and manufacturing capabilities at its Pipeline and Platform Day.
13 Σεπ 2022 · The biopharmaceutical company announces plans to discontinue its ongoing Phase 1 trials of RTX-240 and RTX-224 for advanced solid tumors and shift to a next generation red blood cell-based cell conjugation platform. The new platform aims to improve efficacy, versatility and cost of Red Cell Therapeutics for cancer and autoimmune diseases.
